The role of β-adrenergic receptors in the regulation of cardiac tolerance to ischemia/reperfusion. Why do β-adrenergic receptor agonists and antagonists protect the heart?
Leonid N MaslovNatalia V NaryzhnayaNikita S VoronkovBoris K KurbatovIvan A DerkachevVyacheslav V RyabovEvgeny V VyshlovViktor V KolpakovEugenia A TomilovaEkaterina V SapozhenkovaNirmal SinghFeng FuJianming PeiPublished in: Fundamental & clinical pharmacology (2024)
It is unclear why β-blockers with the similar receptor selectivity have the infarct-sparing effect while other β-blockers with the same selectivity do not affect infarct size. What is the molecular mechanism of the infarct-reducing effect of β-blockers in reperfusion? Why did in early studies β-blockers decrease the mortality rate in patients with acute myocardial infarction (AMI) and without reperfusion and in more recent studies β-blockers had no effect on the mortality rate in patients with AMI and reperfusion? The creation of more effective β-AR ligands depends on the answers to these questions.
Keyphrases
- acute myocardial infarction
- angiotensin converting enzyme
- percutaneous coronary intervention
- left ventricular
- angiotensin ii
- cardiovascular events
- heart failure
- risk factors
- coronary artery disease
- cerebral ischemia
- atrial fibrillation
- cardiovascular disease
- case control
- type diabetes
- robot assisted
- acute ischemic stroke
- brain injury
- subarachnoid hemorrhage